The main objective of this work was to quantify the expression of some genes (C-MYC, N-MYC, SPT16, AURKA, AURKB) that are more characteristic biomarkers for neuroblastoma with poor prognosis, but less studied in AML patients, including carriers of FLT3-ITD mutation with high allelic load. This evidence concerns the gene MYCN and acute myeloid leukemia.